Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 18Phase NA 7Phase 1/2 3Phase 2/3 2Phase 1 2Phase EARLY_PHASE1 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 125Breast Neoplasms 82Neoplasms 78Colorectal Neoplasms 67Neoplasm Metastasis 65Prostatic Neoplasms 61Leukemia, Myeloid, Acute 61Ovarian Neoplasms 57Recurrence 55Pancreatic Neoplasms 55Multiple Myeloma 52Melanoma 40Triple Negative Breast Neoplasms 36Lung Neoplasms 36Glioblastoma 36Squamous Cell Carcinoma of Head and Neck 34Endometrial Neoplasms 33Lymphoma, Non-Hodgkin 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Lymphoma, Large B-Cell, Diffuse 28Carcinoma, Renal Cell 28Lymphoma 27Stomach Neoplasms 26Small Cell Lung Carcinoma 26Carcinoma, Hepatocellular 26Myelodysplastic Syndromes 25Lymphoma, B-Cell 25Advanced Solid Tumor 25Leukemia, Lymphocytic, Chronic, B-Cell 24Brain Neoplasms 24

Interventions

toripalimab 1spartalizumab 1anlotinib 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Nasopharyngeal Carcinoma × 90 days × Clear all
NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 1/2 Recruiting
148 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT07247201 2026-03-30

AlloNK1

Singapore General Hospital

Phase 1/2 Not yet recruiting
31 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT07320963 2026-03-20

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Sun Yat-sen University

Phase 1/2 Not yet recruiting
52 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡